Drug Search Results
More Filters [+]

Lumefantrine

Alternative Names: lumefantrine
Latest Update: 2024-04-04
Latest Update Note: Clinical Trial Update

Product Description

Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy.  (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Lumefantrine)

Mechanisms of Action: Hematin Inhibitor,Nucleic Acid Synthesis Inhibitor,Protein Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Chile | China | Ecuador | Egypt | France | Greece | India | Indonesia | Ireland | Japan | Malaysia | Netherlands | New Zealand | Pakistan | Peru | Portugal | Slovenia | South Africa | Spain | Sweden | Switzerland | Thailand | Ukraine | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Ministry of Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lumefantrine

Countries in Clinic: Australia, Bangladesh, Burkina Faso, Cambodia, Congo, Gabon, Gambia, Guinea, Kenya, Mali, Niger, Nigeria, Rwanda, Tanzania, Thailand, United Kingdom

Active Clinical Trial Count: 11

Highest Development Phases

Phase 3: Malaria, Falciparum

Phase 2: Malaria

Phase 1: HIV Infections|Hepatitis B|Pregnancy Outcomes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ALAQ

P1

Recruiting

Pregnancy Outcomes|HIV Infections|Hepatitis B

2026-08-31

CHMI-TransMod

P2

Active, not recruiting

Malaria, Falciparum

2025-12-01

KALUMI

P2

Recruiting

Malaria, Falciparum

2024-05-28

24%

KALUMI

P2

Recruiting

Malaria, Falciparum

2024-05-28

24%

DeTACT-Africa

P3

Recruiting

Malaria, Falciparum

2024-03-15

Recent News Events